newsfilter
← Latest News
Business Wire·

AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference

  • AtriCure, Inc. (ATRC) will participate in the upcoming J.P. Morgan 44th Annual Healthcare Conference.
  • AtriCure's management is scheduled to present on Wednesday, January 14, 2026, at 10:30 a.m. Pacific Standard Time.
  • Interested parties can access a live audio webcast via the "Investors" section of the company's website at https://ir.atricure.com.
  • Afib affects more than 59 million people worldwide, & AtriCure technologies are used globally for Afib treatment, LAA management, & post-operative pain management.
  • The Isolator® Synergy™ Ablation System is the first FDA-approved device for treating persistent Afib.
  • The AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
  • Hybrid AF™ Therapy is a minimally invasive procedure designed to provide lasting solutions for long-standing persistent Afib patients.
  • cryoICE cryoSPHERE® & cryoXT® probes are cleared for temporary ablation of peripheral nerves to block pain in cardiac, thoracic, & amputation procedures.